An investigation of the association between lipoxin A4 levels and metabolic syndrome parameters in patients with metabolic syndrome
Abstract views: 150 / PDF downloads: 26
Keywords:Lipoxin A4, metabolic syndrome, metabolic syndrome parameters
Aim: Metabolic syndrome (MS) is a significant public health problem and has the potential to increase the risk of developing cardiovascular diseases (CVD), the risk of type 2 Diabetes Mellitus (T2DM), the risk of stroke and the risk of a heart attack. MS has recently been considered an inflammatory disease. Lipoxins (LXs) are, on the other hand, bioactive lipid molecules synthesized from arachidonic acid (AA) and show potent anti-inflammatory and pro-resolving activities in vivo and in vitro conditions. In this study, we aimed to evaluate serum levels of LXA4 in MS patients and explore the relationship of serum LXA4 levels with MS components [waist circumference, blood pressure, serum high-density lipoprotein (HDL), and triglyceride (TG) levels].
Material and Method: In this study, the sample was composed of 39 patients diagnosed with MS and 32 healthy age- and sex-matched individuals. We measured serum LXA4 levels adopting the enzyme-linked immunosorbent assay (ELISA) method with “Human Lipoxin A4 ELISA Kit”. While collecting the blood samples from the subjects, we noted their ages, sex, physical examination findings, and anthropometric measurements [height, weight, waist circumference, and body mass index (BMI)]. Additionally, we obtained their serum TG, low-density lipoprotein (LDL), HDL, glucose, and cholesterol levels.
Results: While we could not find any significant differences between the groups by age and sex (p>0.05), the groups significantly differed by weight, waist circumference, BMI, systolic blood pressure, diastolic blood pressure, TG, HDL, and FBG (p<0.05 for TG; p<0.001 for others). Moreover, serum levels of LXA4 significantly differed between the groups (p<0.05). Within-group comparisons showed that while serum levels of LXA4 significantly differed between male subjects (p=0.01), it was not the case for females (p>0.05). In both groups, there were negative correlations between serum LXA4 levels and waist circumference (r=-0.368 p=0.02). Yet, we found such an association only among male patients (r=-0.516 p=0.02).
Conclusion: Overall, we found serum LXA4 levels to be significantly low in MS patients (p<0.05). Yet, it still needs to be elucidated whether this impairment is a cause or a result of MS. Finally, we discovered this impairment and its significant correlations with some MS parameters to be only in male patients, suggesting that serum LXA4 levels may vary by sex in MS patients.
Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014; 2014: 943162.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet 2005; 366: 1059-62.
Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-100.
Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-35.
R. Monteiro. “Chronic inflammation in the metabolic syndrome: emphasis on adipose tissue.” in Oxidative Stress. Inflammation and Angiogenesis in the Metabolic Syndrome. R. Soares and C. Costa. Eds. 2009. pp. 65–83. Springer Science. Nerw York. NY. USA.
Romano M, Recchia I, Recchiuti A. Lipoxin Receptors Eicosanoid Receptors and Inflammation. Sci World J 2007; 7: 1393–412.
Fiore S, Serhan CN. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J Exp Med 1990; 172: 1451-7.
Serhan CN. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity?. Prostaglandins. 1997; 53: 107-37.
Serhan CN. Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J Thromb Haemost 2009; 7: 44-8.
Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 2005; 102: 7671-6.
Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008; 3: 279-312.
Maderna P, Godson C. Lipoxins: resolutionary road. Br J Pharmacol 2009; 158: 947-59.
International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. http: //www.idf.org/metabolic-syndrome.
Levy BD, Kohli P, Gotlinger K, et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 2007; 178: 496-502.
Karp CL, Flick LM, Park KW, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004; 5: 388-92.
Xu Z, Zhao F, Lin F, et al. Preeclampsia is associated with a deficiency of lipoxin A4, an endogenous anti-inflammatory mediator. Fertil Steril 2014; 102: 282-90.
Feuerstein G, Siren AL. Mesenteric vascular responses to i.v. administration of lipoxin A4 and lipoxin B4 in the conscious rat. FEBS Lett. 1988; 232: 51-5.
Su X, Feng X, Terrando N, et al. Dysfunction of inflammation-resolving pathways is associated with exaggerated postoperative cognitive decline in a rat model of the metabolic syndrome. Mol Med 2013; 18: 1481-90.
Titos E, Clària J. Omega-3-derived mediators counteract obesity-induced adipose tissue inflammation. Prostaglandins Other Lipid Mediat 2013; 107: 77-84.
Titos E. Rius B. González-Périz A. et al. Resolvin D1 and its precursordocosahexaenoic acid promote resolution of adipose tissue inflammation byeliciting macrophage polarization toward an M2-like phenotype. J Immunol 2011; 15: 5408–18.
González-Périz A. Horrillo R. Ferré N. et al. Obesity-induced insulin resistanceand hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvinsand protectins. FASEB J 2009; 23: 1946–57.
Neuhofer A, Zeyda M, Mascher D, et al. Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes 2013; 62: 1945- 56.
Mauro CR, Ilonzo G, Nguyen BT, et al. Attenuated adiposopathy in perivascular adipose tissue compared with subcutaneous human adipose tissue. Am J Surg 2013; 206: 241-4.
Lin F, Zeng P, Xu Z. Treatment of Lipoxin A4 and its analogue on low-dose endotoxin induced preeclampsia in rat and possible mechanisms. ReprodToxicol 2012: 34; 677–85.
Sobrado M, Pereira MP, Ballesteros I. Synthesis of Lipoxin A4 by 5-Lipoxygenase Mediates PPARγ- Dependent. Neuroprotective Effects of Rosiglitazone in Experimental Stroke. J Neurosci 2009; 29: 3875-84.
Yu D, Xu Z, Yin X, et al. Inverse Relationship between Serum Lipoxin A4 Level and the Risk of Metabolic Syndrome in a Middle-Aged Chinese Population. PLoS One 2015; 10: e0142848.
Kim OS, Shin MH, Kweon SS, et al. The severity of periodontitis and metabolic syndrome in Korean population: the Dong-gu study. J Periodontal Res 2018; 53: 362-8.
Doğan ESK, Doğan B, Fentoğlu Ö, Kırzıoğlu FY. The role of serum lipoxin A4 levels in the association between periodontal disease and metabolic syndrome. J Periodontal Implant Sci 2019; 49: 105-13.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.